CorMedix (CRMD) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
CorMedix (CRMD) has outperformed Wave Life Sciences (WVE) over the past year, losing 28.7% versus a loss of 59.9%. Over five years, CRMD leads with a +52.8% price change compared with -27.9% for WVE. Wave Life Sciences is the larger company by market cap ($616.8 million vs $565.9 million), about 1.1 times the size, while CorMedix is growing revenue faster (+617.0% vs -60.5%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -478.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | WVE |
|---|---|---|
| Share price | $7.26 | $3.13 |
| Market cap | $565.88M | $616.76M |
| 1-day change | -2.68% | -1.88% |
| YTD return | -37.58% | -81.59% |
| 1-year return | -28.68% | -59.92% |
| 5-year return | +52.84% | -27.88% |
| P/E ratio (TTM) | 3.54 | — |
| Forward P/E | 20.74 | — |
| EPS (TTM) | $2.05 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $42.73M |
| Revenue growth (YoY) | +617.03% | -60.55% |
| Net income (latest FY) | $163.06M | $-204.38M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -504.09% |
| Net margin | 52.31% | -478.33% |
| 52-week high | $13.02 | $21.73 |
| 52-week low | $6.13 | $3.04 |
| Distance from 52-week high | -44.24% | -85.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.16% | +450.16% |
| Average volume | 1.11M | 3.17M |
| Shares outstanding | 77.94M | 197.05M |
| Employees | 191 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed WVE by 31.2 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -478.3 cents for Wave Life Sciences.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -60.55%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
CRMD vs WVE FAQ
Which is bigger, CorMedix or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $616.76M compared with $565.88M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or WVE?
CRMD returned -28.68% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.